Sugi Predict

Sugi Predict / Compounds / SCHEMBL400586

SCHEMBL400586

SCHEMBL400586

COC[C@H]1CN(Cc2ccc(F)c(NC(=O)Nc3ccc(C)nc3)c2)CCN1S(C)(=O)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CA P42336 2/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ GALR3 O60755 1/20 0.39
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ TP53 P04637 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ CHEK1 O14757 4/20 0.36
▸ MAPK8 P45983 3/20 0.36
▸ MAPK10 P53779 3/20 0.36
▸ CCR3 P51677 3/20 0.36
▸ FPR1 P21462 1/20 0.35
▸ FPR2 P25090 1/20 0.35
▸ NAMPT P43490 1/20 0.35
▸ KCNQ3 O43525 1/20 0.35
▸ KCNQ2 O43526 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401449 0.93 RAB9A (0.38) PIK3CARAB9AGALR3MEN1KMT2A
SCHEMBL23573861 0.90 PIK3CA (0.40) PIK3CARAB9AGALR3MEN1KMT2A
SCHEMBL29714033 0.88 MEN1 (0.39) RAB9AGALR3MEN1KMT2ANPC1
SCHEMBL29714054 0.88 MEN1 (0.39) RAB9AGALR3MEN1KMT2ANPC1
SCHEMBL3204584 0.88 RAB9A (0.39) RAB9AGALR3MEN1KMT2ANPC1
SCHEMBL400632 0.88 FPR1 (0.39) RAB9AGALR3MEN1KMT2ANPC1
SCHEMBL3208975 0.88 RAB9A (0.39) RAB9AGALR3MEN1KMT2ANPC1
SCHEMBL398545 0.88 FPR1 (0.39) RAB9AGALR3MEN1KMT2ANPC1
SCHEMBL401736 0.86 RORC (0.39) RAB9AGALR3MEN1KMT2ANPC1
SCHEMBL397956 0.86 RAB9A (0.38) RAB9AGALR3MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US claimed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US claimed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US claimed
EP-2862859-A2 Compounds, compositions and methods Cytokinetics, Inc. (US) 2015-04-22 — — EP claimed
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2015-01-01 — — US claimed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US claimed
US-12264133-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2025-04-01 — — US disclosed
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
EP-1765327-A2 COMPOUNDS, COMPOSITIONS AND METHODS Cytokinetics, Inc. (US) 2007-03-28 — — EP disclosed
WO-2006009726-A2 SUBSTITUTED UREA DERIVATIVES FOR TREATING CARDIAC DISEASES CYTOKINETICS, INC. (US) 2006-01-26 — — WO disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 PIK3CA 4067/4885RAB9A 3170/4885GALR3 4019/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 PIK3CA 3286/4885RAB9A 2091/4885GALR3 4620/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 PIK3CA 3564/4885RAB9A 2773/4885GALR3 4008/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 PIK3CA 3564/4885RAB9A 2773/4885GALR3 4008/4885
US-12264133-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 PIK3CA 3564/4885RAB9A 2773/4885GALR3 4008/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 PIK3CA 3564/4885RAB9A 2773/4885GALR3 4008/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 PIK3CA 4067/4885RAB9A 3170/4885GALR3 4019/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 PIK3CA 2144/4885RAB9A 3510/4885GALR3 1699/4885
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 PIK3CA 3564/4885RAB9A 2773/4885GALR3 4008/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 PIK3CA 3564/4885RAB9A 2773/4885GALR3 4008/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 PIK3CA 3564/4885RAB9A 2773/4885GALR3 4008/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 PIK3CA 3564/4885RAB9A 2773/4885GALR3 4008/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 PIK3CA 3564/4885RAB9A 2773/4885GALR3 4008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.